PRECLINICAL STUDIES OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IMATINIB IN BRCA STRATIFIED OVARIAN CANCER

被引：0
|
作者：
Matheson, E. [1 ]
Salehan, M. [1 ]
Mukhopadhyay, A. [1 ]
Curtin, N. J. [1 ]
Drew, Y. [1 ]
机构：
[1] Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2016年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IGCS-0943
引用
收藏
页码：673 / 673
页数：1
相关论文
共 50 条
  • [41] A preclinical evaluation of niraparib efficacy as monotherapy, maintenance and after olaparib treatment (PARP inhibitor after PARP inhibitor) in patient-derived ovarian xenograft tumor models
    Mikule, K.
    Wang, S.
    Weroha, S. J.
    Nakashima, J.
    Wilcoxen, K.
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 72 : S96 - S96
  • [42] An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
    Xu, Jing
    Gao, Yi
    Luan, Xiaotian
    Li, Ke
    Wang, Jing
    Dai, Yilin
    Kang, Mingyi
    Lu, Chong
    Zhang, Minhua
    Lu, Chris X.
    Kang, Yu
    Xu, Congjian
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (05) : 683 - 695
  • [43] The Nampt inhibitor MPC-9528 and the PARP inhibitor olaparib synergize in killing a BRCA-deficient cancer cell line
    Terry-Lorenzo, R. T.
    Fleischer, T. C.
    Lockman, J. W.
    Boniface, J. J.
    Willardsen, J. A.
    Carlson, R. O.
    [J]. EJC SUPPLEMENTS, 2010, 8 (07): : 4 - 5
  • [44] Anti-tumor effects in combination with PARP inhibitor and DNMT inhibitor in ovarian cancer
    Lee, Jeong-Won
    Jeong, Soo Young
    Ryu, Ji Yoon
    Lee, Yoo-Young
    Esun, Paik
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [45] An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
    Jing Xu
    Yi Gao
    Xiaotian Luan
    Ke Li
    Jing Wang
    Yilin Dai
    Mingyi Kang
    Chong Lu
    Minhua Zhang
    Chris X. Lu
    Yu Kang
    Congjian Xu
    [J]. Cancer Chemotherapy and Pharmacology, 2022, 89 : 683 - 695
  • [46] Olaparib for BRCA-mutated advanced ovarian cancer
    de Lartigue, Jane
    [J]. JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2015, 13 (06): : 206 - 208
  • [47] Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer
    Henneman, Linda
    van Miltenburg, Martine H.
    Michalak, Ewa M.
    Braumuller, Tanya M.
    Jaspers, Janneke E.
    Drenth, Anne Paulien
    de Korte-Grimmerink, Renske
    Gogola, Ewa
    Szuhai, Karoly
    Schlicker, Andreas
    Bin Ali, Rahmen
    Pritchard, Colin
    Huijbers, Ivo J.
    Berns, Anton
    Rottenberg, Sven
    Jonkers, Jos
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (27) : 8409 - 8414
  • [48] Preclinical evaluation of the PARP inhibitor rucaparib in combination with PD-1 and PD-L1 inhibition in a syngeneic BRCA1 mutant ovarian cancer model
    Robillard, Liliane
    Nguyen, Minh
    Loehr, Andrea
    Orsulic, Sandra
    Kristeleit, Rebecca S.
    Lin, Kevin
    Raponi, Mitch
    Harding, Thomas C.
    Simmons, Andrew D.
    [J]. CANCER RESEARCH, 2017, 77
  • [49] Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
    Yang, Shicheng
    Green, Allen
    Brown, Needa
    Robinson, Alexis
    Senat, Merline
    Testino, Bryanna
    Dinulescu, Daniela M.
    Sridhar, Srinivas
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [50] Synergistic Effect of Bazedoxifene and PARP Inhibitor in the Treatment of Ovarian Cancer Regardless of BRCA Mutation
    Zhang, Ruijie
    Wang, Tiffany
    Lin, Jiayuh
    [J]. ANTICANCER RESEARCH, 2021, 41 (05) : 2277 - 2286
12345